Nicole S. White Sells 1,255 Shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) Stock

Assembly Biosciences, Inc. (NASDAQ:ASMB - Get Free Report) insider Nicole S. White sold 1,255 shares of the stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $12.71, for a total transaction of $15,951.05. Following the sale, the insider now directly owns 13,025 shares of the company's stock, valued at $165,547.75. The sale was disclosed in a document filed with the SEC, which is available through this link.

Assembly Biosciences Trading Up 6.4 %

Shares of ASMB stock traded up $0.80 on Wednesday, reaching $13.27. The company's stock had a trading volume of 12,137 shares, compared to its average volume of 26,402. The company has a market capitalization of $72.72 million, a price-to-earnings ratio of -0.78 and a beta of 0.57. The stock's fifty day simple moving average is $13.17 and its 200-day simple moving average is $11.15. Assembly Biosciences, Inc. has a 1 year low of $7.69 and a 1 year high of $20.04.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on ASMB shares. StockNews.com raised shares of Assembly Biosciences from a "sell" rating to a "hold" rating in a report on Friday, April 5th. HC Wainwright reissued a "neutral" rating on shares of Assembly Biosciences in a report on Monday, April 1st.

Institutional Trading of Assembly Biosciences

An institutional investor recently bought a new position in Assembly Biosciences stock. Marquette Asset Management LLC purchased a new position in Assembly Biosciences, Inc. (NASDAQ:ASMB - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 54,464 shares of the biopharmaceutical company's stock, valued at approximately $45,000. Marquette Asset Management LLC owned about 0.08% of Assembly Biosciences as of its most recent SEC filing. 19.92% of the stock is owned by hedge funds and other institutional investors.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's next-generation HBV core inhibitors include ABI-4334, which is in Phase 1a studies for the treatment of HBV; and ABI-H3733, which is in Phase 1b clinical study.